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Prosthesis Sets a New Standard*
Howard C. Herrmann, MDW hen Cribier et al. (1) ﬁrst described trans-catheter aortic valve replacement(TAVR) for aortic stenosis (AS) in 2002,
few envisioned the current widespread utilization of
this novel technique. Initial randomized studies pro-
vided evidence for efﬁcacy in patients not suitable
for open surgical aortic valve replacement (2,3).
Subsequent studies demonstrated noninferiority (4)
and then superiority (5) to surgery for high-risk
patients. Nonetheless, limitations of TAVR, particu-
larly vascular complications, stroke, and paravalvular
leaks (PVL) resulting in aortic regurgitation (AR),
have combined to restrict TAVR to patients with
high or high-intermediate risk for surgery (6).
A breakthrough in technology or in the procedure
is needed if TAVR is to continue to march down the
risk proﬁle curve. The SAPIEN 3 balloon-expandable
prosthesis (Edwards Lifesciences Inc., Irvine, Cali-
fornia) may be the spark that raises the bar for other
prostheses to match and allows cardiologists and
cardiothoracic surgeons to feel comfortable extend-
ing this technology to truly intermediate and low-risk
surgical patients with AS.SEE PAGE 2235In this issue of the Journal, Webb et al. (7) report
the ﬁrst multicenter experience at 16 Canadian and
European sites with SAPIEN 3 in 150 high- (ﬁrst 50
patients) and intermediate-risk subjects with a mean
age of 84 years and Society of Thoracic Surgeons*Editorials published in the Journal of the American College of Cardiology
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Devices, Inc.(STS) predicted risk for 30-day mortality of 7.4%. This
next-generation device has a balloon-expandable
cobalt-chromium frame with bovine pericardial leaf-
lets and an external fabric seal. It is one of the lowest
proﬁle devices under investigation in the United
States. The use of trancatheter alternative access
was surprisingly high at 36%, partly by study design.
Nevertheless, the results in the transfemoral (TF)
subgroup—96% fully percutaneous—were remarkable.
In the 96 TF patients, the rate of all-cause mortality
was 2.1% (1.1% in those with a valve implanted), all
strokes 1.0%, major vascular complications 4.2%,
and moderate PVL/AR 3.5%, with no patient having
severe AR (7). Red ﬂags raised by this study in-
clude the high use of alternative access with less
favorable results due in part to the higher-risk pro-
ﬁle of these subjects, a minor vascular complication
rate of close to 20% even in TF patients, mild AR in
22%, and a new permanent pacemaker rate that
is higher than usually seen for balloon-expandable
devices at 13.3%.
What are the implications of these ﬁndings for
TAVR with this device? First, transfemoral access
should be the default strategy for the great majority
of operators and patients. Early data with larger de-
vices suggested equivalence and some advantages to
alternative access approaches, namely fewer vascular
complications and potentially fewer strokes (8).
However, with smaller devices, increasing experience
with femoral closure devices, monitored anesthesia
care, and learning curve issues with alternative ac-
cess, it has become clear that patients recover faster
with percutaneous TF access and have similar or
fewer complications (9), including possibly improved
survival (10). In the present study, 30-day mortality
was 10-fold higher (11.1%) in patients who had alter-
native (non-TF) access, despite similar STS risk
scores. The present report does not make clear why
alternative access was used so frequently nor the
TABLE 1 30-Day Outcomes in Selected TAVR Trials
Trial (Ref. #) N
STS
Score Mortality
All
Stroke
$ Moderate
AR
Major
Vascular
Complications
New
PPM
PARTNER IB (2) 179 11.2 5.0 6.7 11.8 16.2 3.4
PARTNER IA (4) 348 11.8 3.4 4.7 12.2 11.0 3.8
PARTNER IIB (14) 284 10.3 3.5 4.3 24.0 9.6 6.4
STS/ACC TVT registry (6) 3,528 7.0 7.6 2.8 — — 6.6
CoreValve extreme (3) 489 10.3 8.4 4.0 15.3 8.2 21.6
CoreValve pivotal (4) 390 7.3 3.3 4.9 10.0 5.9 19.8
SAPIEN 3 (7) 150 7.4 5.3 2.7 3.5 5.3 13.3
SAPIEN 3 TF cohort (7) 96 7.5 2.1 1.0 3.5 4.2 12.5
Values are % unless otherwise indicated.
ACC ¼ American College of Cardiology; AR ¼ aortic regurgitation; PARTNER ¼ Placement of Aortic Trans-
catheter Valve; PPM ¼ new permanent pacemaker; STS ¼ Society of Thoracic Surgeons; TAVR ¼ transcatheter
aortic valve replacement; TF ¼ transfemoral; TVT ¼ transcatheter valve therapy.
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risk patients.
Second, the data of Webb et al. (7) create disap-
pointment and dissatisfaction with the second-
generation devices currently available. It is clear
that moderate and severe AR, and in some studies
mild AR, after TAVR reduces medium-term survival
(11–13). Debate will continue on the methodology for
assessment (12) and the rates of PVL between the
commercially available devices (13), but as shown in
Table 1 comparing the largest randomized trials of
TAVR devices as well as the U.S. STS/American Col-
lege of Cardiology Transcatheter Valve Therapy high-
risk registry, the best case scenario with TF SAPIEN 3
has set a new standard for the worst complications
of TAVR, creating hunger for this and other new
prostheses. In the United States, it is hoped that the
results of the high- and intermediate-risk registries
with this new device will reproduce these results
and garner rapid U.S. Food and Drug Administration
approval. In this regard, as the authors point out,
while awaiting the results of the randomized PART-
NER II (Placement of Aortic Transcatheter Valve)
trial Cohort A (NCT01314313) and SURTAVI (Surgical
Replacement and Transcatheter Aortic Valve Im-
plantation; NCT01586910) trials in intermediate-risk
patients, these data provide justiﬁcation for the
ongoing nonrandomized SAPIEN 3 intermediate-risk
cohort registry of the PARTNER II trial.
One can now envision that this and other third-
generation TAVR devices will move this procedure
into low intermediate- and truly low-risk patients.TAVR may then become the treatment of choice for
the majority of patients with severe and symptomatic
AS. However, the excitement that this new device
provides to the TAVR community should be tempered
by the lack of data on long-term durability, a perma-
nent pacemaker rate higher than observed with pre-
vious balloon-expandable valves, and the residual
mild AR rate. Nonetheless, the bar has been raised
and a new standard for TAVR results has been set.
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